Bivatuzumab ( —— )

产品货号. M36909 CAS No. 214559-60-1

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

产品询价大包装询价加入购物车

产品名称

Bivatuzumab
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) 是一种靶向 CD44v6 的人源化单克隆抗体。CD44v6 可作为 CAR 重定向 CIK 细胞的肉瘤靶点。
产品描述

Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells.
体外实验

Bivatuzumab (10 μg/mL) stains CD44v6 in STS cells.
体内实验

——
同义词

——
通路

Others
靶点

Other Targets
受体

Others
研究领域

——
适应症

——

1. Leuci V,et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167. ?

计算器

产品手册

关联产品

Citreorosein

Citreorosein is a cAMP phosphodiesterase inhibitor, it has anti-inflammatory effect, inhibits proinflammatory cytokines production through the inhibition of both MAPKs and AKT-mediated IκB kinase (IKK) phosphorylation and subsequent inhibition of transcription factor NF-κB activation.
Flucycloxuron

Flucycloxuron 是一种甲壳素合成抑制剂，用作农药。在昆虫模型中，该抑制剂已被证明会影响多种生殖事件，例如产卵前的持续时间。
Parimifasor

Parimifasor（LYC-30937-EC，LYC30937）是一种口服生物可利用的肠溶 ATP 酶调节剂，作为肠道定向疗法用于治疗炎症性肠病 (IBD)。